Real-World Study Demonstrated Economic Benefits of Pegfilgrastim Biosimilar for the Prevention of Febrile Neutropenia
Shots:
- The real-world study evaluates the cost-effectiveness of pegfilgrastim biosimilars vs filgrastim biosimilars in patients with high & intermediate risk of FN
- In both groups, PEG led to 0.28 & 0.12 QALYs gained, 0.32 & 0.14 LYs gained, 0.43 & 0.18 FN events prevented/patient. Additionally, a reduction in FN incidence resulted in lower costs for inpatient FN management in the high-risk groups, PEG reference products were also superior to FIL reference product
- In both groups, the use of pegfilgrastim biosimilars could optimize the management of FN risk. Pegfilgrastim biosimilar was cost-saving over filgrastim biosimilar for the high-risk group & remained dominant for the intermediate-risk group
Ref: The Center For Biosimilars | Image: Healio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
